Skip to main content

2017 Global Summit & Gala

The FAST Global Summit & Gala draws more than 1,000 attendees from around the world. The annual event features a science summit, an education summit and an AAC carnival, and the weekend concludes with a star-studded gala recognized as Chicago’s largest celebrity fundraiser. Scroll down and click on the links below to watch presentations from the 2017 Summit, and remember to mark your calendar for the 2018 Summit, which kicks off Dec. 7.

FAST Science Summit [bookmark id="science-summit"]

FAST’s Science Summit provides an opportunity to interact directly with the scientists, researchers, and pharmaceutical and biotechnology company leaders working on a cure for Angelman syndrome, while getting up to speed on all of the latest developments and breakthroughs in AS research. AAV-mediated gene therapy to the central nervous system: prospect for Angelman syndrome James M. Wilson, M.D., Ph.D., Rose H. Weiss professor and director, Orphan Disease Center; director, Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania Gene therapy round table: ask the experts Arthur L. Beaudet, M.D., Baylor College of Medicine Scott Dindot, Ph.D., Texas A&M University Kevin Nash, Ph.D., University of South Florida David Segal, Ph.D., University of California, Davis Edwin Weeber. Ph.D., University of South Florida James M. Wilson, M.D., Ph.D., Penn Medicine’s Orphan Disease Center Ashley Winslow, Ph.D., Penn Medicine’s Orphan Disease Center Overview of the FAST research agenda for gene therapy and genetic editing in Angelman syndrome Allyson Berent, DVM, DACVIM, chief science officer, FAST The Global Angelman Syndrome Registry Megan Cross, chair, FAST Australia Chloe Simons, chief science officer, FAST Australia Modifying the Bayley test to benefit clinical trials in Angelman syndrome Anjali Sadhwani, Ph.D., clinical psychologist, Boston Children's Hospital Anne Wheeler, Ph.D., public health researcher, RTI International Therapeutic development and outcome measure evaluation using a disease concept model in Angelman syndrome Meagan Miller, Ph.D., discovery project leader, Roche In the clinic: Ovid Therapeutics-OV101 and the engagement with the Angelman community Jeremy Levin, D.Phil., MB BChir, chairman and chief executive officer, Ovid Therapeutics Inc. Amit Rakhit M.D., MBA, chief medical and portfolio officer, Ovid Therapeutics Inc. Approaching the clinic: nutritional support for patients with Angelman syndrome Mike McCandless, founder, Disruptive Nutrition Jessica Duis, M.D., M.S., assistant professor of pediatrics, Vanderbilt University Medical Center Donna Herber, Ph.D., chief science officer, Disruptive Nutrition AAV-mediated gene therapy approach: Ovid Therapeutics Ed Weeber, Ph.D., Ph.D., professor, University of South Florida Jenn Daley, Ph.D., director of research, Agilis Biotherapeutics The Angelman Biomarkers and Outcome Measures Alliance (A-BOM) Terry Jo Bichell, Ph.D., director, Angelman Biomarkers and Outcome Measures Alliance

Education Summit [bookmark id="education-summit"]

The Education Summit provide parents, caregivers, therapists and educators with product demonstrations and information about services that can help improve the quality of life for individuals with Angelman syndrome – and those who care for them. Introduction to augmentative and alternative communication (AAC) Kelly Fonner, M.S., educational assistive technology trainer and consultant Reading and writing in Angelman syndrome Kelly Fonner, M.S., educational assistive technology trainer and consultant Beginning communication is just a tool away – accessing multiple environments through assistive technology Nancy Robinson, Ph.D., Communicative Disorders Program, San Francisco State University Kathleen Sadao, Ed.D., educational consultant Ask the experts panel Kate Ahern, M.S.Ed. Kelly Fonner, M.S. Nancy Robinson, Ph.D. Kathleen Sadao, Ed.D. AAC vendor presentations Prentke Romich Company (PRC), Saltillo and Tobii-Dynavox Understanding anxiety and challenging behaviors in Angelman syndrome Kate Ahern, M.S.Ed., assistive technology specialist Augmentative and alternative communication (AAC) as an intervention to anxiety and challenging behaviors Kate Ahern, M.S. Shibvon Sargent, parent Implementing strategies in the school placement panel Amy Girouard, parent Shari Holt, MHS, CCC-SLP Danielle Williams, B.A., LBS1 Trish Brawley, B.A., LBS1